FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983172312> ?p ?o ?g. }

• W2983172312 endingPage "3055" @default.
• W2983172312 startingPage "3055" @default.
• W2983172312 abstract "Multiple Myeloma (MM) is a plasma cells malignancy with number of recent therapeutic options that has improved outcomes with median survival now stretching beyond 8 years. There has been an intense search to identify genomic and laboratory correlates of outcome for high risk patients. However, a subgroup of patients have a long survival but genomic segmentation of this important group which can be potentially cured has not been identified. We here described first such attempt at identifying a subset of patients with long survival. We have analyzed data from 205 newly-diagnosed uniformly-treated MM patients using both deep whole genome (WGS) (80x) and whole transcriptome sequencing (RNAseq). Median number of SNVs, small insertion and deletion per megabase were 2.18 [0.49 - 14.52], 0.077 [0.024 - 0.17] and 0.12 [0.03 - 0.26] respectively. MM subgroups defined by FISH or copy number alterations (CNAs) had significantly different mutational load (Kruskal-Wallis p-value = 0.003). In general, Hyperdiploid MM (HMM) patients had lower SNV load compared to other subgroups and t(14;16) had the highest mutational load per megabase (Dunn test FDR < 0.25). These subgroups also showed significant differences for mutational process utilization. Mutational processes associated spontaneous deamination of 5-methylcytosine to thymine was significantly high in HMM, APOBEC activity was very strong in t(14;16) MM and DNA repair was significantly different in t(6;14), del17p and t(11;14). Importantly, the mutations associated with clonal cell population and thus in early phases of MM cell progression were driven by spontaneous or enzymatic deamination (Signature 1), somatic hypermutation in lymphoid cells (Signature 9) and Signature 17 (ANOVA p value < 1e-16) and surprisingly APOBEC activity was constant among the clones (ANOVA p value > 0.05). However, mutations associated with homologous recombination (HR) and nucleotide excision repair (NER) activity were significantly enriched in the subclonal mutations (ANOVA p value < 1e-16) suggesting their role in later stages of MM progression. Based on this information, we next calculated the homologous recombination repair defects using copy number alterations from WGS data. We identified that HR score generated using WGS copy number information predicted outcome in newly diagnosed myeloma. Further analysis of this data identified that newly diagnosed MM patients with hyperdiploid MM (HMM) and no HR- repair deficiency have superior outcome with 6 year overall survival (OS) probability for this of 100% in IFM/DFCI 2009 cohort (Logrank test p value = 0.0012). We next validated this finding using MMRF CoMMpass dataset and we confirmed 6-yr OS probability of 95% (Logrank test p value = 0.0016) in this independent dataset (Figure 1). We further investigated RNAseq data between these genomically defined groups and identified that chromosome and telomere maintenance pathways (FDR < 0.01) and low bone disease associated genes described by Zhan et al. (FDR = 0.004) were up regulated in low-risk group. Finally, patients who were able to maintain HR, had lower mutation rate for TP53 (0% vs 9%, FDR < 0.05), CSMD1 (0% vs 6%, FDR < 0.05), FAT3/FAT4 mutations (1.7% vs 15%, FDR < 0.05), however surprisingly higher mutation rate for NRAS (42% vs 14%, p value < 0.001). In addition, DNA damage associated processes predicted by SNVs trinucleotides were significantly lower in the low-risk group (12% vs. 20%, p value < 1e-05) providing further support to this data. In conclusion, we report a detailed genomic profile using deep DNA and RNA sequencing and identify a genomically-defined sub group that is predicted to have a long survival. This study also identifies the role of HR in myeloma with potential for its translational application in both prognosis as well as therapy. Figure 1 Disclosures Richardson: Janssen: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees. Moreau:Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Thakurta:Celgene: Employment, Equity Ownership. Anderson:Sanofi-Aventis: Other: Advisory Board; Bristol-Myers Squibb: Other: Scientific Founder; Oncopep: Other: Scientific Founder; Amgen: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau. Avet-Loiseau:celgene: Consultancy, Other: travel fees, lecture fees, Research Funding; takeda: Consultancy, Other: travel fees, lecture fees, Research Funding. Munshi:Takeda: Consultancy; Oncopep: Consultancy; Adaptive: Consultancy; Amgen: Consultancy; Celgene: Consultancy; Abbvie: Consultancy; Janssen: Consultancy." @default.
• W2983172312 created "2019-11-22" @default.
• W2983172312 creator A5014723513 @default.
• W2983172312 creator A5025996929 @default.
• W2983172312 creator A5028526208 @default.
• W2983172312 creator A5030565933 @default.
• W2983172312 creator A5031149500 @default.
• W2983172312 creator A5032464400 @default.
• W2983172312 creator A5039380390 @default.
• W2983172312 creator A5041002394 @default.
• W2983172312 creator A5043526996 @default.
• W2983172312 creator A5045740077 @default.
• W2983172312 creator A5050977500 @default.
• W2983172312 creator A5062468245 @default.
• W2983172312 creator A5063099799 @default.
• W2983172312 creator A5063422967 @default.
• W2983172312 creator A5063717307 @default.
• W2983172312 creator A5067318207 @default.
• W2983172312 creator A5073612758 @default.
• W2983172312 creator A5087896269 @default.
• W2983172312 date "2019-11-13" @default.
• W2983172312 modified "2023-09-30" @default.
• W2983172312 title "The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma" @default.
• W2983172312 doi "https://doi.org/10.1182/blood-2019-128521" @default.
• W2983172312 hasPublicationYear "2019" @default.
• W2983172312 type Work @default.
• W2983172312 sameAs 2983172312 @default.
• W2983172312 citedByCount "0" @default.
• W2983172312 crossrefType "journal-article" @default.
• W2983172312 hasAuthorship W2983172312A5014723513 @default.
• W2983172312 hasAuthorship W2983172312A5025996929 @default.
• W2983172312 hasAuthorship W2983172312A5028526208 @default.
• W2983172312 hasAuthorship W2983172312A5030565933 @default.
• W2983172312 hasAuthorship W2983172312A5031149500 @default.
• W2983172312 hasAuthorship W2983172312A5032464400 @default.
• W2983172312 hasAuthorship W2983172312A5039380390 @default.
• W2983172312 hasAuthorship W2983172312A5041002394 @default.
• W2983172312 hasAuthorship W2983172312A5043526996 @default.
• W2983172312 hasAuthorship W2983172312A5045740077 @default.
• W2983172312 hasAuthorship W2983172312A5050977500 @default.
• W2983172312 hasAuthorship W2983172312A5062468245 @default.
• W2983172312 hasAuthorship W2983172312A5063099799 @default.
• W2983172312 hasAuthorship W2983172312A5063422967 @default.
• W2983172312 hasAuthorship W2983172312A5063717307 @default.
• W2983172312 hasAuthorship W2983172312A5067318207 @default.
• W2983172312 hasAuthorship W2983172312A5073612758 @default.
• W2983172312 hasAuthorship W2983172312A5087896269 @default.
• W2983172312 hasBestOaLocation W29831723121 @default.
• W2983172312 hasConcept C104317684 @default.
• W2983172312 hasConcept C126322002 @default.
• W2983172312 hasConcept C141231307 @default.
• W2983172312 hasConcept C143998085 @default.
• W2983172312 hasConcept C150194340 @default.
• W2983172312 hasConcept C162317418 @default.
• W2983172312 hasConcept C203014093 @default.
• W2983172312 hasConcept C2776162770 @default.
• W2983172312 hasConcept C2776364478 @default.
• W2983172312 hasConcept C2779399171 @default.
• W2983172312 hasConcept C2908647359 @default.
• W2983172312 hasConcept C54355233 @default.
• W2983172312 hasConcept C71924100 @default.
• W2983172312 hasConcept C86803240 @default.
• W2983172312 hasConcept C99454951 @default.
• W2983172312 hasConceptScore W2983172312C104317684 @default.
• W2983172312 hasConceptScore W2983172312C126322002 @default.
• W2983172312 hasConceptScore W2983172312C141231307 @default.
• W2983172312 hasConceptScore W2983172312C143998085 @default.
• W2983172312 hasConceptScore W2983172312C150194340 @default.
• W2983172312 hasConceptScore W2983172312C162317418 @default.
• W2983172312 hasConceptScore W2983172312C203014093 @default.
• W2983172312 hasConceptScore W2983172312C2776162770 @default.
• W2983172312 hasConceptScore W2983172312C2776364478 @default.
• W2983172312 hasConceptScore W2983172312C2779399171 @default.
• W2983172312 hasConceptScore W2983172312C2908647359 @default.
• W2983172312 hasConceptScore W2983172312C54355233 @default.
• W2983172312 hasConceptScore W2983172312C71924100 @default.
• W2983172312 hasConceptScore W2983172312C86803240 @default.
• W2983172312 hasConceptScore W2983172312C99454951 @default.
• W2983172312 hasIssue "Supplement_1" @default.
• W2983172312 hasLocation W29831723121 @default.
• W2983172312 hasOpenAccess W2983172312 @default.
• W2983172312 hasPrimaryLocation W29831723121 @default.
• W2983172312 hasRelatedWork W2002128513 @default.
• W2983172312 hasRelatedWork W2007674596 @default.
• W2983172312 hasRelatedWork W2355902447 @default.
• W2983172312 hasRelatedWork W2435227317 @default.
• W2983172312 hasRelatedWork W2789881781 @default.
• W2983172312 hasRelatedWork W2919381586 @default.
• W2983172312 hasRelatedWork W3000738194 @default.
• W2983172312 hasRelatedWork W3025961873 @default.
• W2983172312 hasRelatedWork W3029979236 @default.
• W2983172312 hasRelatedWork W4232652152 @default.
• W2983172312 hasVolume "134" @default.
• W2983172312 isParatext "false" @default.
• W2983172312 isRetracted "false" @default.
• W2983172312 magId "2983172312" @default.
• W2983172312 workType "article" @default.